Anidulafungin

Slone Partners Places Cynthia Pussinen as Chief Executive Officer and Member of the Board of Directors at Sernova Corporation

Retrieved on: 
Thursday, September 14, 2023
Sequence, Actinium, University, United Board for Christian Higher Education in Asia, Change, Bachelor of Science in Human Biology, Drug development, Therapy, Spark, Master of Science in Respiratory Care, Health, Licensure, Research, Anidulafungin, Chemistry, Honeywell, Rensselaer Polytechnic Institute, Patient, Engineering, European, Roche, Management, Science, Ipsen

SOUTH RIDING, Va., Sept. 14, 2023 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, healthcare, and cybersecurity organizations, has announced the placement of Cynthia Pussinen as Chief Executive Officer (CEO) and a member of the Board of Directors at Sernova Corporation, a clinical-stage company and leader in cell therapeutics.

Key Points: 
  • SOUTH RIDING, Va., Sept. 14, 2023 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life sciences, healthcare, and cybersecurity organizations, has announced the placement of Cynthia Pussinen as Chief Executive Officer (CEO) and a member of the Board of Directors at Sernova Corporation , a clinical-stage company and leader in cell therapeutics.
  • Pussinen's expertise spans the drug development continuum from research through commercialization.
  • Most recently, Pussinen served as Chief Technical Officer for Spark Therapeutics, Inc., a fully integrated, commercial gene therapy company, and a member of the Roche Group.
  • "She will make for a terrific addition to the Sernova leadership team and Board of Directors during a pivitol stage in the company's evolution."

Sernova Corporation Announces the Appointment of Cynthia Pussinen as CEO

Retrieved on: 
Tuesday, September 5, 2023
Sequence, Actinium, University, United Board for Christian Higher Education in Asia, Bachelor of Science in Human Biology, Operation, Executive, Drug development, FSE, Therapy, Spark, Master of Science in Quality Management and Analytics, WEST, Health care, Licensure, PSH, Research, Anidulafungin, Type 1 diabetes, Chemistry, National Science Board, Honeywell, HBA, Rensselaer Polytechnic Institute, Patient, Engineering, European, TSX, Conditional sentence, Health, Woman, Pfizer, Roche, Management, Pharmaceutical industry, Nursing, Science, T1D, Ipsen

LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that its Board of Directors has appointed Cynthia Pussinen as Chief Executive Officer and a member of the Board of Directors. Dr. Philip Toleikis, who has led the company since 2009 as President and CEO will serve as Chief Technology Officer.

Key Points: 
  • Dr. Philip Toleikis, who has led the company since 2009 as President and CEO will serve as Chief Technology Officer.
  • Most recently, Ms. Pussinen was the Chief Technical Officer for Spark Therapeutics, Inc., a fully integrated, commercial gene therapy company, and a member of the Roche Group.
  • I am very pleased to welcome Ms. Pussinen to the Sernova team as the new CEO and look forward to working together.
  • Sernova’s management will host investor calls, firstly to introduce Ms. Pussinen, and later, in approximately 30 days, to provide an overview of Sernova as well as a question-and-answer session.

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

Retrieved on: 
Monday, August 8, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, PNH, Dermatology, Multimedia, U.S. Securities and Exchange Commission, Risk, Institute of Liver and Biliary Sciences, Kansas State University, Hematology, NDA, Drug discovery, Industry, CEO, Human, Senior, AbbVie, RSV, University, COVID, Leadership, HBV, Infection, Ravulizumab, Marshall Scholarship, Patent, Yale School of Medicine, Security (finance), Atypical hemolytic uremic syndrome, Research, Respiratory syncytial virus, Yale school, Marketing, Glecaprevir/pibrentasvir, COVID-19, Neurology, Drug development, Voriconazole, NASDAQ, Paroxysmal nocturnal hemoglobinuria, Nephrology, Anidulafungin, Rheumatology, Mayo Clinic Alix School of Medicine, Hepatitis B virus, Medication, Tigecycline, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, HCV, Food, MAA, Pharmaceutical industry, Alexion, Pfizer, Biology

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022.
  • View the full release here: https://www.businesswire.com/news/home/20220808005491/en/
    Scott T. Rottinghaus, M.D., Senior Vice President and Chief Medical Officer, Enanta Pharmaceuticals (Photo: Business Wire)
    We are delighted to welcome Scott Rottinghaus to our senior management team.
  • Earlier in his Pfizer career, he worked as a clinician on early stage clinical trials for influenza vaccine development.
  • Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release.